Brainstorm Cell Therapeutics Inc (NAS:BCLI)
$ 0.516 0.032 (6.61%) Market Cap: 35.26 Mil Enterprise Value: 33.05 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 39/100

Q2 2021 Brainstorm Cell Therapeutics Inc Earnings Call Transcript

Aug 05, 2021 / 12:00PM GMT
Release Date Price: $3.94 (+4.51%)
Operator

Good day, ladies and gentlemen, and welcome to BrainStorm Cell Therapeutics' second-quarter 2021 earnings call. (Operator Instructions) It is my now my pleasure to turn the floor to your host, Thomas Galassi. Sir, the floor is yours.

Thomas Galassi
LifeSci Advisors, LLC - IR

Good morning, and thank you everyone for joining us. Before we begin the opening remarks, we would like to remind listeners that this conference call contains numerous statements, descriptions, forecasts, and projections regarding BrainStorm Cell Therapeutics and its potential future business operations and performance, statements regarding the market potential for the treatment of neurodegenerative diseases such as ALS and MS, the sufficiency of the company's existing capital resources for continuing operations in 2021 and beyond, the safety and clinical effectiveness of the NurOwn technology platform, clinical trials of NurOwn and related clinical development programs, and the company's ability to develop strategic collaborations and partnerships to support their business planning efforts

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot